|
業務類別
|
Biotechnology |
|
業務概覽
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR. |
| 公司地址
| 250 East Grand Avenue, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 338-3533 |
| 傳真號碼
| -- |
| 公司網頁
| https://septerna.com |
| 員工數量
| 75 |
| Dr. Jeffrey T. Finer, M.D.,PhD |
Chief Executive Officer and Director |
美元 550.19K |
04/08/2025 |
| Dr. Uwe Klein, PhD |
Senior Vice President, Biological Sciences |
-- |
29/04/2025 |
| Mr. Gil M. Labrucherie |
Chief Financial Officer and Principal Accounting Officer |
-- |
06/01/2025 |
| Ms. Ran Xiao, C.F.A. |
Vice President, Finance and Business Operations |
-- |
06/01/2025 |
| Dr. Daniel Long, D.Phil. |
Senior Vice President, Drug Discovery |
-- |
29/04/2025 |
| Ms. Samira Shaikhly |
Chief People Officer |
-- |
29/04/2025 |
| Dr. Jae B. Kim, M.D. |
Chief Medical Officer |
美元 125.06K |
29/04/2025 |
| Ms. Liz Bhatt |
Chief Operating Officer and President |
美元 449.56K |
04/08/2025 |
|
|
| Dr. Jake Simson, PhD |
Independent Director |
29/04/2025 |
| Dr. Keith Gottesdiener, M.D. |
Independent Director |
29/09/2025 |
| Dr. Jeffrey T. Finer, M.D.,PhD |
Chief Executive Officer and Director |
04/08/2025 |
| Ms. Shalini Sharp |
Independent Director |
29/04/2025 |
| Mr. Abraham Bassan |
Independent Director |
29/04/2025 |
| Dr. Alan Ezekowitz, M.D.,PhD |
Director |
29/04/2025 |
| Dr. Jeffrey K. Tong, PhD |
Chairman of the Board |
29/04/2025 |
| Dr. Bernard Coulie, M.B.A.,M.D.,PhD |
Independent Director |
29/04/2025 |
|
|
|
|
